Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Embion Technologies is a Swiss EPFL spin-out developing industrial biotechnology and green chemistry solutions that convert underutilized lignocellulosic and food-industry biomass into high-value bioactive ingredients. The company positions itself as a platform business built around a patented ionic catalyst process for clean, scalable biomass breakdown and rapid product prototyping. Its lead commercial product, PREMBION, is a natural microbiome modulator for the animal protein industry designed to improve gut health, support feed efficiency, and reduce reliance on antibiotics. Beyond animal nutrition, Embion markets its platform for applications in food, nutraceuticals, cosmetics, pharma, materials, and broader circular-bioeconomy uses. The company appears to be a private, active, venture-backed business headquartered in Etoy/Lausanne, Switzerland.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Embion Technologies.